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Pregnancy-associated cardiac dysfunction
and the regulatory role of microRNAs
Laila Aryan†, Lejla Medzikovic†, Soban Umar and Mansoureh Eghbali*
Abstract
Many crucial cardiovascular adaptations occur in the body during pregnancy to ensure successful gestation.
Maladaptation of the cardiovascular system during pregnancy can lead to complications that promote cardiac
dysfunction and may lead to heart failure (HF). About 12% of pregnancy-related deaths in the USA have been
attributed to HF and the detrimental effects of cardiovascular complications on the heart can be long-lasting, pre-
disposing the mother to HF later in life. Indeed, cardiovascular complications such as gestational diabetes mellitus,
preeclampsia, gestational hypertension, and peripartum cardiomyopathy have been shown to induce cardiac
metabolic dysfunction, oxidative stress, fibrosis, apoptosis, and diastolic and systolic dysfunction in the hearts of
pregnant women, all of which are hallmarks of HF. The exact etiology and cardiac pathophysiology of pregnancy-
related complications is not yet fully deciphered. Furthermore, diagnosis of cardiac dysfunction in pregnancy is
often made only after clinical symptoms are already present, thus necessitating the need for novel diagnostic and
prognostic biomarkers. Mounting data demonstrates an altered expression of maternal circulating miRNAs during
pregnancy affected by cardiovascular complications. Throughout the past decade, miRNAs have become of
growing interest as modulators and biomarkers of pathophysiology, diagnosis, and prognosis in cardiac
dysfunction. While the association between pregnancy-related cardiovascular complications and cardiac dysfunction
or HF is becoming increasingly evident, the roles of miRNA-mediated regulation herein remain poorly understood.
Therefore, this review will summarize current reports on pregnancy-related cardiovascular complications that may
lead to cardiac dysfunction and HF during and after pregnancy in previously healthy women, with a focus on the
pathophysiological role of miRNAs.
Keywords: Pregnancy, MicroRNA, Gestational diabetes, Peripartum cardiomyopathy, Pre-eclampsia, Gestational
hypertension, Heart failure, Cardiac dysfunction
Introduction
During pregnancy, various crucial adaptations in the car-
diovascular system occur which are necessary for the
progression of successful gestation [1]. Maladaptation of
the cardiovascular system during pregnancy in previ-
ously healthy women can lead to complications that may
cause maternal and fetal mortality [2, 3]. Cardiovascular
complications during pregnancy may put the mother at
risk to develop cardiac dysfunction and subsequent heart
failure (HF) [2, 4]. These complications include meta-
bolic changes such as gestational diabetes mellitus
(GDM), hypertensive disorders such as preeclampsia
(PE) and gestational hypertension (GH), and cardiac
structural changes such as peripartum cardiomyopathy
(PPCM) [5–8]. Cardiac complications in pregnancy are
becoming increasingly common [9]. In the USA, about
12% of pregnancy-related deaths have been attributed to
cardiac dysfunction, and having cardiac dysfunction dur-
ing pregnancy has been associated with a 7.7-fold in-
crease in the risk of death [9, 10]. Furthermore, the
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adverse effects of cardiovascular complications on the
heart can be long-lasting, pre-disposing the mother to
HF later in life [11, 12].
The heart undergoes several structural, metabolic, and
functional changes during pregnancy to accommodate
the enhanced cardiac output necessary for meeting ma-
ternal and fetal demands [13]. These changes are distinct
from adverse cardiac remodeling which precedes HF
[14]. However, GDM, PE, GH, and PPCM have all been
shown to induce cardiac metabolic dysfunction, oxida-
tive stress, fibrosis, apoptosis, and diastolic and systolic
dysfunction in the hearts of pregnant women, all of
which are hallmarks of HF [14]. The underlying molecu-
lar cardiac pathophysiology of these complications is not
yet fully elucidated and warrants further investigation.
Furthermore, diagnosis of cardiac dysfunction and HF in
pregnancy is often made only after clinical symptoms
are already present, thus necessitating the need for novel
diagnostic and prognostic biomarkers.
MicroRNAs (miRNAs) are small, non-coding RNAs
that regulate gene expression at the post-transcriptional
level by binding to the 3’ untranslated region (3′ UTR)
of the target mRNA, marking it for early degradation or
blocking its translation [15]. MiRNAs are highly con-
served between different species and may control mul-
tiple signaling pathways at once [16]. Mounting data
demonstrates altered circulating miRNA expression in
pregnancy affected by cardiovascular complications [17,
18]. Throughout the past two decades, circulating and
tissue-specific miRNAs have become of growing interest
as modulators and biomarkers of pathophysiology, diag-
nosis, and prognosis in a variety of cardiovascular disor-
ders including HF [19, 20]. Although a significant
number of studies have been published on the associ-
ation between GDM, PE, GH, PPCM, and cardiac dys-
function or HF, miRNA-mediated regulation herein
remains poorly understood.
This review will discuss current reports on pregnancy-
related cardiovascular complications that may lead to
cardiac dysfunction and HF during and after pregnancy
in previously healthy women, with a focus on the patho-
physiological role of miRNAs.
Physiological cardiovascular changes during
pregnancy
Hemodynamics of the maternal cardiovascular system
during pregnancy
The maternal cardiovascular system undergoes several
changes during pregnancy. Blood flow increases to meet
the metabolic needs of the maternal organs and fetus
[13]. Blood volume increases approximately 45% above
pre-pregnancy levels [1]. Stroke volume, heart rate, and
end-diastolic volume all increase, resulting in enhanced
cardiac output [1]. Indeed, cardiac output rises up to
50% above pre-pregnancy levels at about 16–20 weeks of
gestation [21]. Both systolic and diastolic arterial blood
pressure decrease in the first and second trimesters [21,
22]. However, arterial blood pressure rises in the third
trimester, returning to baseline by the end of pregnancy
[22]. To meet these hemodynamic changes during preg-
nancy, the heart undergoes structural and functional
changes.
Structural and metabolic changes in the heart during
pregnancy
Natural volume overload, mechanical stretch, and hor-
monal changes during pregnancy induce physiological
cardiac hypertrophy [23–25]. In contrast to pathological
cardiac hypertrophy, pregnancy-induced physiological
cardiac hypertrophy is characterized by proportional in-
creases in cardiomyocyte size and therefore growth in
left ventricular (LV) wall thickness and chamber di-
mensions [24]. Importantly, myocardial capillary dens-
ity remains normal. Furthermore, pregnancy-induced
physiological hypertrophy is not associated with fibro-
sis, cardiomyocyte sarcomere disarray, or enhanced
re-expression of the cardiac fetal gene program [24].
Notably, the changes in cardiac structure and function
during normal healthy pregnancy are rapidly reversed
post-partum [26].
Metabolic changes in the heart during pregnancy are
in contrast to those in pathological cardiac hyper-
trophy and HF. HF is characterized by a switch from
myocardial fatty acid oxidation as a main source of en-
ergy to enhanced utilization of glucose [27]. Animal
models in various studies have demonstrated that
pregnancy is associated with a decrease in cardiac glu-
cose utilization and increased utilization of fatty acids
[28–30]. However, a decrease in cardiac fatty acid oxi-
dation genes has also been reported [31]. Interestingly,
cardiac insulin signaling and mitochondrial function
remain unaltered in pregnancy-induced hypertrophy in
mice, while they are depressed in pathological cardiac
hypertrophy and HF [28, 32, 33].
Signaling pathways regulating the cardiac phenotype
during pregnancy
Cardiac molecular signaling pathways activated in
pregnancy-induced hypertrophy are distinct from those
activated during pathological hypertrophy [23]. Some of
these pathways have been demonstrated to be regulated
by miRNAs. The best characterized miRNA-regulated
pathways in pregnancy-induced cardiac hypertrophy in-
clude phosphoinositide-3-kinase/protein kinase B/glycogen
synthase kinase 3β (PI3K/Akt/ GSK3β) signaling, mitogen-
activated protein kinase (MAPK) signaling, calcineurin sig-
naling, and signal transducer and activator of transcription
3 (STAT3) signaling [34, 35].
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Phosphoinositide 3-kinase (PI3K), protein kinase B (Akt),
and glycogen synthase kinase 3 beta (GSK3β)
The PI3K/Akt pathway has been demonstrated as an im-
portant mediator in pregnancy-induced cardiac hyper-
trophy in several studies. The major target of PI3K/Akt
signaling is GSK3β, an inhibitor of pathological cardiac
hypertrophic signaling that becomes inactivated by Akt-
mediated phosphorylation [36]. A large number of studies
suggest that PI3K/Akt/GSK3β signaling is cardio-protective
and mediates physiological rather than pathological cardiac
hypertrophy. All three components of the signaling cascade
have been shown to be of great importance for cardio-
protection. Indeed, mice with cardiomyocyte-specific ex-
pression of constitutively active forms of PI3K and Akt
respectively have been shown to develop cardiac hyper-
trophy with preserved contractility and systolic function,
without cell death or fibrosis [37–41]. Furthermore, male
mice with cardiomyocyte-specific expression of dominant-
negative forms of PI3K and Akt respectively have a dimin-
ished physiological hypertrophic response, but enhanced
hypertrophy and cardiac dysfunction in response to pres-
sure overload by transverse aortic constriction (TAC) [38,
39]. Akt activation, as measured by phosphorylation status,
is upregulated in the LV of pregnant mice and rats, during
mid- and late pregnancy [34, 42]. In contrast, one study has
also reported the downregulation of phosphorylated Akt in
the hearts of pregnant rats compared to non-pregnant rats,
which is restored postpartum [43]. This discrepancy could
be explained by differences in the estrus cycle of non-
pregnant control animals since estrogen levels vary during
the estrus cycle in non-pregnant mice [44]. Estrogen is also
known to activate MAPK and PI3K/Akt pathways [45, 46].
We have shown previously that estrogen increases tyrosine
kinase c-Src activity (phosphorylation) in the heart mimick-
ing increased c-SRC activity in the late pregnant heart
[47]. In addition to GSK3β, other targets of PI3K/Akt
signaling, such as the mammalian target of rapamycin
(mTOR) and ribosomal S6 protein kinase (p706SK)
have also been demonstrated to be upregulated in mouse
hearts in mid-pregnancy [34]. Interestingly, compared to
wild type (WT), mice expressing constitutively-active Akt
had larger hearts when non-pregnant which did not
undergo further hypertrophy [34]. Along the same lines,
mice expressing constitutively active, inhibiting, GSK3β
were blocked in their hypertrophic response to pregnancy
[34]. Taken together, both Akt and GSK3β are important
mediators of pregnancy-induced cardiac hypertrophy [34].
Mitogen-activated protein kinases (MAPKs)
During pregnancy, hormonal changes and mechanical
stretch of cardiomyocytes alter the activation of several
MAPK signaling pathways [34, 48]. MAPKs mediate
various cellular responses in the healthy and diseased
heart including hypertrophy, apoptosis, proliferation,
differentiation, survival, and inflammatory responses
[49]. In the heart, extracellular signal-regulated kinase
(ERK) is protective against adverse remodeling, while
p38 MAPK and c-Jun N-terminal kinase (JNK) are asso-
ciated with stress responses [24, 34, 49]. Additionally,
crosstalk between ERK and p38 and JNK MAPKs regu-
lates various processes in the heart [49]. Various transgenic
mouse models illustrate the importance of MAPK in
physiological cardiac hypertrophy. Mice expressing cardiac-
specific constitutively active MAPK kinase 1 (MEK1), a dir-
ect upstream activator of ERK1/2, but that does not activate
JNK and p38, exhibit cardiac hypertrophy with enhanced
cardiac function without decompensation over time, remin-
iscent of physiological cardiac hypertrophy [50]. However,
mice lacking the p38 upstream regulator apoptosis signal-
regulating kinase 1 were shown to exhibit less adverse
cardiac remodeling upon pressure overload by TAC,
but more pronounced physiological hypertrophy com-
pared to WT mice [51]. ERK phosphorylation, and thus
activation, is shown to be increased in LV of early preg-
nant rats and mid-pregnant mice [29, 34, 42]. In contrast,
phosphorylation of JNK and p38 MAPK are decreased in
the hearts of pregnant rats and mice [34, 43]. Further-
more, in pregnant rats, cardiac p-p38 and p-JNK levels
were shown to be negatively associated with lower LV
mass/volume ratio [43].
Calcineurin
Calcium-dependent phosphatase calcineurin is well-known
to be upregulated in human hypertrophic and failing hearts
and acts as a mediator of adverse cardiac remodeling by me-
diating nuclear translocation of the pro-hypertrophic tran-
scription factor nuclear factor of activated T-cells (NFAT)
[52, 53]. Elevated cardiac calcineurin expression and activity
have been demonstrated in early pregnancy, which is par-
tially induced by hormonal changes [54]. Blocking calcine-
urin using cyclosporine A diminishes the development of
pregnancy-induced physiological cardiac hypertrophy in
mice [54]. Interestingly, calcineurin inhibition also blocks
pregnancy-induced cardiac ERK1/2 and activation [54].
While calcineurin levels remain elevated in pathological
hypertrophy and HF, by late pregnancy cardiac calcineurin
levels decrease dramatically [31, 54].
Signal transducer and activator of transcription 3 (STAT3)
STAT3 is an important cardio-protective signaling mol-
ecule and the transcription factor involved in the patho-
physiology of various cardiac diseases [55, 56]. As a
transcription factor, STAT3 activates several anti-apoptotic,
anti-oxidative, and pro-angiogenic genes in the heart [55].
Interestingly, STAT3 has been shown to both activate and
inhibit fibrotic and inflammatory genes in the heart, most
likely due to differences in post-translational modifications,
and cellular localization [55, 57–60]. Furthermore, STAT3
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has been shown to alter miRNA expression in both the
male and female hearts [61, 62]. The non-genomic actions
of STAT3 include, among others, a protective function in
mitochondria by regulating reactive oxygen species (ROS)
production [56, 63]. In mouse heart during pregnancy and
postpartum, STAT3 activation, as determined by phosphor-
ylation status, has been shown to be protective in a number
of pregnancy-related cardiac insults [64–67].
Cardiac pathophysiology of cardiovascular
complications during pregnancy
Cardiovascular complications reflect an inability to adapt
to the various changes in systemic physiology that are as-
sociated with pregnancy [3]. While cardiovascular compli-
cations in pregnancy may affect multiple organ systems
including the liver, kidneys, and brains [68, 69], we focus
on the adverse effects on the heart. Indeed, metabolic
changes in GDM, elevated blood pressure, and vascular
resistance in PE and GH, and LV structural and functional
changes in PPCM may all negatively affect cardiac func-
tion and may promote HF development [5–8].
Gestational diabetes mellitus (GDM)
Maintaining glucose homeostasis is of utmost importance
during pregnancy for maternal and fetal health as it ensures
sufficient glucose levels to promote fetal development while
simultaneously maintaining maternal nutrition [69]. GDM
is characterized by de novo hyperglycemia occurring in the
second or third trimester despite having no previous history
of diabetes mellitus [69]. The prevalence of GDM is in-
creasing in parallel with the rise of maternal age and obes-
ity, and is reported to affect approximately 5–14% of
pregnancies in the USA [70].
Impaired glucose homeostasis is common in patients
with HF even in the absence of hyperglycemia and is likely
to contribute to disease progression [71]. As such, GDM
was found to be independently associated with greater LV
mass, impaired LV relaxation, and LV systolic function
[5]. However, GDM patients have also been shown to dis-
play only LV diastolic filling impairment without changes
in LV mass or systolic function [72]. Strikingly, a history
of GDM is associated with a ~ 2-fold increased risk of de-
veloping HF up to 25 years postpartum [73–75].
Several factors contribute to the pathophysiology of
GDM, including insulin resistance, pancreatic β-cell dys-
function, and elevated hepatic gluconeogenesis. Insulin
resistance results in impaired plasma membrane trans-
location of glucose transporter 4 (GLUT4), the primary
transporter that is responsible for shuttling glucose into
the cell as an energy source [76]. While insulin resistance
decreases during normal pregnancy, insulin-stimulated
glucose uptake is reported to drop by an extra 54% in
GDM patients compared with normal pregnant controls,
leading to hyperglycemia [76, 77]. It is important to note
that there is a strong association between body weight and
insulin resistance in pregnancy [78]. Women weighing
more than 95 kg between 24 and 32 weeks of gestation
were reported to have significantly higher levels of severe
insulin resistance and in turn, a higher risk of GDM [78].
Indeed, in GDM patients, downstream regulators of insu-
lin, including PI3K and GLUT4, have all been shown to be
alternatively expressed or activated compared to healthy
controls [77]. An increase in serine phosphorylation of in-
sulin receptor substrate has been demonstrated in weeks
30 through 34 of gestation. This leads to a decrease in in-
sulin receptor substrate association with insulin receptor
and can inhibit PI3K activity, which in turn, inhibits insu-
lin signaling from activating GLUT4 translocation [79].
Adaptation of insulin-producing pancreatic β cells is crit-
ical for a proper response to pregnancy-related insulin re-
sistance and includes increased β cell number, size, and
insulin secretion [80]. The adaptation of β cells is thought
to be mediated by maternal and placental hormones in-
cluding prolactin [80]. Prolactin signals through the Akt/
mTOR pathway to reduce β cell apoptosis and enhance
glucose-stimulated insulin secretion, and through the
ERK/MAPK pathway to enhance β cell proliferation [80].
In late gestation, where insulin resistance is at its peak, the
maternal system shifts towards a pro-inflammatory im-
mune state [81], which can have adverse outcomes as β
cells can be susceptible to macrophage infiltration [82].
However, the mechanism responsible for the inability of β
cells to compensate in GDM is yet unknown [80]. During
pregnancy, hepatic gluconeogenesis rates increase in
healthy women and GDM patients [83, 84]. Together with
impaired insulin secretion and sensitivity, higher levels of
hepatic gluconeogenesis result in the hyperglycemia ob-
served in GDM patients [69].
Limited research has been conducted on the molecular
cardiac pathophysiology of GDM. Recently, GDM was in-
duced in pregnant mice by intraperitoneal injection of
streptozotocin (STZ) [85]. Here, retinoic acid treatment at-
tenuated STZ-induced cardiac hypertrophy and fibrosis by
enhancing expression of mitochondrial superoxide dismut-
ase (mnSOD), decreasing oxidative stress and reactive oxy-
gen species (ROS) levels, and dampening NF-κB signaling
[85]. Changes in LV structure and function reported in
GDM are similar to those in diabetic cardiomyopathy [86].
As such, it is tempting to hypothesize that GDM cardiac
pathophysiology includes dysregulated insulin/PI3k/Akt/
mTOR-mediated autophagy, MAPK-mediated inflamma-
tion, mitochondrial dysfunction, apoptosis, and cardiac
microvascular dysfunction as is observed in diabetic cardio-
myopathy [86].
Preeclampsia (PE) and gestational hypertension (GH)
In the USA, up to 10% of all pregnancies are compli-
cated by hypertensive disorders [87]. Ranging in severity,
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hypertensive pregnancy disorders can be classified as
preeclampsia-eclampsia, gestational hypertension, pre-
existing chronic hypertension, and PE superimposed on
pre-existing chronic hypertension [88]. Here, we will
focus on de novo-developed PE and GH.
Preeclampsia (PE)
PE complicates 5 to 7% of pregnancies and remains the
main cause of maternal and fetal morbidity and mortal-
ity [89]. Up to now, the only definitive treatment for PE
is delivery of the fetus and placenta; however, in some
cases, PE can persist or develop postpartum [68]. Cur-
rently, PE is diagnosed based on de novo hypertension
after 20 weeks of gestation with a systolic BP of ≥ 140
mmHg or diastolic BP ≥ 90 mmHg, and in severe cases
≥ 160 mm /≥ 110 mmHg [68]. Furthermore, at least one
other symptom indicating maternal organ dysfunction
including kidney, liver, neurological and hematological
complications, will be present [68, 87].
Elevated systemic vascular resistance in PE may ad-
versely affect cardiac structure and function and as such,
PE is associated with both short- and long-term cardio-
vascular events, including adverse cardiac remodeling
and HF [6]. In various stages of disease progression, PE
patients have been reported to exhibit decreased cardiac
output, higher LV afterload, increased LV mass and LV
wall thickness and LV diastolic dysfunction [90–98].
Strikingly, women with previous early-onset of pre-
eclampsia have significantly higher fasting blood glucose,
insulin, triglycerides, and total cholesterol levels as com-
pared to women with late-onset preeclampsia at the time
of follow-up even 3 months postpartum [99]. The increase
in these risk factors indicates a higher risk of future CVD
in women with previous early-onset preeclampsia [99].
These results highlight the significance of early prevention
for patients with preeclampsia.
The exact etiology of PE is still controversial, but pla-
cental ischemia seems to play a central role in its onset
[68]. The later phase in PE pathophysiology is character-
ized by elevated circulating levels of the anti-angiogenic
factors, a pro-inflammatory state and alterations in the
renin-angiotensin pathway and sympathetic nervous sys-
tem (SNS) [68]. The anti-angiogenic soluble fms-like
tyrosine kinase-1 (sFLT1) exerts its effects by binding to
the pro-angiogenic protein vascular endothelial growth
factor (VEGF) and placental growth factor (PIGF), thus
inhibiting their biological activity and causing systemic
endothelial dysfunction [100, 101]. Soluble endoglin
(sENG) is a transforming growth factor-β1 (TGF-β1) in-
hibitor and may potentiate sFLT1 vascular effects [102].
Reduced levels of anti-inflammatory cytokine IL-10 and
elevated complement system signaling in PE patients
contribute to a pro-inflammatory state in PE [103, 104].
Enhanced sensitivity to angiotensin II has been reported
in PE patients, despite reduced circulating renin and
angiotensin II levels [105]. Furthermore, PE patients
are reported to exhibit elevated sympathetic nerve ac-
tivity [106]. Together, these changes lead to a high
systemic vascular resistance state and hypertension in
the mother [68, 107].
Novel players have recently emerged in the cardiac
pathophysiology of PE. Mutations in the atrial natriuretic
peptide-converting enzyme, also known as corin, and
transcription factor storkhead box 1 (STOX1) have been
shown to associate with PE [108, 109]. Recent studies
using transgenic mouse models of corin and STOX1
have demonstrated their role in PE-induced cardiac
pathology [110, 111]. Corin-deficient mice or mice ex-
pressing mutated corin developed cardiac hypertrophy
during pregnancy which persisted postpartum [110].
Pregnant mice with feto-placental STOX1 overexpres-
sion developed cardiac hypertrophy with enhanced fibro-
sis, together with the upregulation of genes involved in
renin-angiotensin signaling [111].
Gestational hypertension (GH)
GH is a form of hypertension that appears de novo after
20 weeks of gestation, but in contrast to PE, does not in-
volve dysfunction of other organ systems [87]. GH af-
fects 6 to 7% of pregnancies and is diagnosed as systolic
BP of ≥ 140 mmHg or diastolic BP ≥ 90 mmHg without
proteinuria [87, 89]. While GH is a risk factor for PE, it
is important to note that GH and PE are separate disor-
ders. It is yet unclear whether GH etiology is distinct
from PE. However, the inflammatory response signature
is shown to be different between patients with GH and
PE [112].
Cardiac LV structure and function in GH patients is
altered compared to normotensive pregnant women. Pa-
tients suffering from GH have been reported to exhibit
reduced ejection fraction (EF), alterations in end-systolic
volume, increased LV mass and wall thickness, and LV
diastolic dysfunction in varying degrees [7, 95, 113–117].
However, cardiac impairments in GH patients are not as
large as in PE patients, likely because PE is not encom-
passed by hypertension alone, but rather a multi-organ
system disorder [7]. Like with PE, women with a history
of GH remain at an increased risk of developing HF later
in life [118].
Peripartum cardiomyopathy (PPCM)
PPCM is a rare but life-threatening pregnancy-related
cardiac disease which presents itself with HF secondary
to LV dysfunction, either towards the end of pregnancy
or within five months postpartum [119, 120]. The inci-
dence of PPCM is approximately 1 in 1000–4000 live births
in the USA and is diagnosed as an EF < 45% [8, 120]. While
women often recover to normal cardiac function, long-
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lasting morbidity and mortality are present in up to 77% of
PPCM patients [8, 121–124]. The exact etiology of PPCM
is yet unknown; however, hormonal and vascular changes,
as well as genetics seem to play a role [8]. Key features of
PPCM pathophysiology include oxidative stress, endothelial
dysfunction, angiogenic imbalance, and inflammatory reac-
tions [125].
The anti-angiogenic 16-kDa N-terminal fragment of
the nursing hormone prolactin (16 kDa-PRL) has been
identified as a potential driving factor of PPCM [64].
Prolactin may be cleaved by cathepsin D [64]. Elevated
serum levels of cathepsin D were found in PPCM pa-
tients and PPCM mouse models [64, 126]. Accordingly,
16 kDa-PRL levels are upregulated in the serum of
PPCM patients and suppression of PRL secretion from
the pituitary with the dopamine D2 receptor agonist
bromocriptine had a beneficial effect in clinical trials on
PPCM outcome [64, 127, 128]. How 16-kDa-PRL causes
vascular dysfunction remains unclear, but is thought to
involve inhibition of pro-angiogenic mediator plasmino-
gen activator-1 (PAI-1) and regulation of miRNA ex-
pression [62, 129]. Enhanced 16-kDa-PRL levels in
PPCM are thought to be caused by impaired activation
of STAT3. Cardiomyocyte-specific STAT3-deficient
mice develop PPCM [64]. Cardiac cathepsin D expres-
sion is elevated in these female STAT3-deficient mice,
which is associated with enhanced production of 16-
kDa-PRL. It was demonstrated that STAT3 deficiency
led to diminished levels of mnSOD in cardiomyocytes,
leading to increased oxidative stress that promotes the
release of cathepsin D [64]. As a result, cardiomyocyte-
specific STAT3-deficient female mice exhibited en-
hanced cardiac fibrosis, endothelial cell death, decreased
cardiac capillary density and systolic dysfunction [64].
Importantly, decreased myocardial STAT3 expression
was found concomitant with elevated serum cathepsin D
and 16 kDa-PRL in PPCM patients [64].
Another factor participating in PPCM pathophysiology is
the imbalance of pro-angiogenic VEGF and anti-angiogenic
sFlt1 [125, 130]. The peroxisome proliferator-activated
receptor-gamma coactivator 1-alpha (PGC-1α) is a tran-
scriptional regulator of metabolic and angiogenic pathways
in numerous tissues, including the heart [131]. Similar to
STAT3 cardiac knockout mice, mice lacking PGC-1α in
cardiomyocytes develop PPCM [130]. PGC-1α-deficient fe-
male mice exhibit decreased secretion of VEGF from cardi-
omyocytes, thus dramatically lowering the threshold for
cardiac sFLT1 toxicity. Stimulation of sFLT1 caused en-
hanced systolic dysfunction in cardiomyocyte PGC-1α-
deficient mice, while only affecting diastolic dysfunction in
WT mice [130]. Importantly, plasma levels of sFLT were
enhanced in PPCM patients compared to healthy pregnant
women [130]. Additionally, part of PPCM pathophysiology
is attributable to PGC-1α-deficiency causing mnSOD
downregulation and thus elevated oxidative stress and car-
diac capillary dysfunction [130].
Inflammation has also been proposed as a possible
underlying mechanism of PPCM pathophysiology [125].
Elevated plasma levels of pro-inflammatory cytokines
such as c-reactive protein (CRP), interleukin-6 (Il-6),
tumor necrosis factor-α (TNF-α), and interferon-γ
(IFN-γ) have been found in PPCM patients and were
shown to positively correlate with cardiac dysfunction
[121, 126, 132].
Finally, a recent genetic study has identified 26 distinct
truncating variants in eight genes in PPCM patients as
compared to the reference population [133]. The majority
of the identified truncating variants were in the titin gene
and were observed in 10% of PPCM patients compared to
~ 1% in the reference population [133]. The sarcomeric
protein, titin, contributes to homeostasis of sarcomere
structure and is essential for coordinated cardiomyocyte
contraction [134]. Interestingly, deleterious titin mutations
have also been found in similar proportions in patients
with idiopathic dilated cardiomyopathy [133].
Cardiac-related miRNAs in pregnancy-related
cardiovascular complications
While up to 75% of the genome is transcribed into RNA,
only 2% of the genome consists of protein-coding genes
[15]. Consequently, non-coding RNAs, and in particular
small non-coding miRNAs, have emerged as critical reg-
ulators of cellular processes in both health and disease
[15]. In turn, many miRNAs are dynamically regulated
by disease states. Indeed, numerous studies have shown
changes in miRNA profiles during pregnancy with com-
plications [17, 18]. Various cell types actively secrete
miRNAs into the circulation, and thus can both mediate
crosstalk between different cell-types or organs, and sim-
ultaneously represent disease biomarkers [135]. It has
been shown that many miRNAs that are differentially
expressed in maternal serum or plasma originate from
the placenta [136, 137]. Since miRNAs are well-known
to mediate various crucial processes in HF development
[19], it is appealing to hypothesize that at least part of
the cardiac dysfunction and HF pathophysiology in
pregnancy-related complications may be mediated by
miRNAs.
Dysregulated miRNAs in gestational diabetes mellitus
Several circulating miRNAs have been shown to be
expressed differentially in patients with GDM. Here, we
will discuss those miRNAs which have already been im-
plicated in the pathophysiology of diabetic cardiomyop-
athy or other forms of adverse cardiac remodeling and
HF (Fig. 1 and Table 1).
Serum miRNAs are expressed differentially per trimes-
ter between healthy pregnant and GDM patients [138].
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In the first trimester, miR-125b-5p expression is shown
to be elevated in the serum of GDM patients compared
to healthy pregnant women and normalizes in the sec-
ond and third trimesters [138]. Patients with acute myo-
cardial infarction (MI) are reported to have elevated
serum miR-125b-5p levels compared to controls [154].
However, in the mouse heart, miR-125b-5p was shown
to play a role in protection against MI by repressing
pro-apoptotic genes bak1 andLC3 (klf13) in cardiomyo-
cytes [139]. Two cardio-protective miRs, namely, miR-
183-5p and miR-200b-3p, are shown to be elevated in
GDM serum compared with healthy pregnant control
serum in the first trimester of pregnancy but become
significantly downregulated by the third trimester [138].
Indeed, in the male rat heart, miR-183-5p was shown to
protect against MI by repressing mitochondrial voltage-
dependent anion channel 1 (VDAC1) leading to decreased
apoptosis upon ischemia/reperfusion injury [140]. Inter-
estingly, miR-200b-3p has been shown to protect against
cardiac fibrosis and cardiac dysfunction in STZ-induced
diabetic cardiomyopathy by inhibiting cardiomyocyte
apoptosis via pro-fibrotic CD36 repression [141] and by
inhibiting endothelial-to-mesenchymal transition [142].
Several studies have shown that plasma levels of miR-
21-3p and miR-195-5p are upregulated in GDM patients
compared to controls [143, 144, 146]. While not much is
yet known about the role of miR-21-3p in diabetic car-
diomyopathy thus far, miR-21-3p is shown to play a role
in cardiac hypertrophy and HF. MiR-21-3p protects
against cardiac hypertrophy in male mice by regulating
histone deacetylase 8 (HDAC8) expression and Akt/
Gsk3β signaling, important for growth control in the
cardiovascular system [145]. It has been shown that
miR-195-5p expression is upregulated in the hearts of
STZ-induced diabetic cardiomyopathy in male mice
[147]. Here, silencing of miR-195-5p in STZ mice led to
enhanced expression of pro-survival mediators B cell
lymphoma 2 (BCL-2) and sirtuin 1. Furthermore, cardiac
hypertrophy, ROS, and apoptosis as measured by caspase
3 activity were reduced upon miR-195-5p silencing in
Fig. 1 Dysregulated circulating cardiac-related miRNAs in cardiovascular complications during pregnancy. Depicted miRNAs have been shown to
be involved in animal models of heart disease. GDM, gestational diabetes mellitus; GH, gestational hypertension; miR, microRNA; PE, preeclampsia;
PPCM, peripartum cardiomyopathy
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male STZ mice, while myocardial capillary density and
coronary blood flow were improved [147]. Similarly,
miR-195-5p expression in rat cardiomyocytes is upregu-
lated by high glucose stimulation [148]. Here, it was
shown that silencing miR-195-5p rescues high-glucose-
induced hERG potassium ion channel deficiency by re-
storing serum and glucocorticoid-regulated kinase 1
(SGK1) expression [148].
Expression levels of miR-29a and miR-222 are re-
ported to be significantly reduced in the serum of GDM
patients compared to healthy pregnant controls in simi-
lar gestational weeks [149]. The miR-29 family consists
of 3 members; miR-29a, -b, and -c, and is well-known to
be involved in diabetes mellitus and diabetic cardiomy-
opathy pathophysiology [155]. Interestingly, however,
miR-29 levels are usually elevated in serum and several
tissues of diabetic patients and animal models [155].
Cardiac miR-29a expression is elevated in male Zucker
diabetic fatty (ZDF) rats compared to male Zucker lean
rats and is concomitant with reduced expression of anti-
apoptotic myeloid cell leukemia-1 (mcl-1) gene expression
[150]. Furthermore, miR-29a has been shown to promote
apoptosis in rat myocardial cells stimulated with high glu-
cose by repressing insulin-like growth factor 1 (IGF-1)
[151]. How these reports relate to reduced serum miR-29a
levels in GDM patients remains to be elucidated. Reduced
expression of miR-222 is shown in both patients and ex-
perimental models of adverse cardiac remodeling and HF
[156, 157]. In male mice with diabetic cardiomyopathy,
miR-222 has been shown to diminish cardiac fibrosis and
improve cardiac function [156]. Here, miR-222 mainly
acts by inhibiting endothelial-to-mesenchymal transition
in the myocardial microvasculature by suppressing Wnt/
β-catenin signaling. Furthermore, male mice with indu-
cible cardiomyocyte-specific miR-222 overexpression are
shown to be protected against ischemia-reperfusion injury
by preserving cardiac structure and function while de-
creasing scar formation [152]. Here, miR-222 inhibits
apoptosis by directly targeting cyclin-dependent kinase in-
hibitor p27, homeodomain interacting protein kinase 1
(HIPK1), and Hmbox-1 in cardiomyocytes [152]. In con-
trast, it has been reported that male mice overexpressing
Table 1 Differentially expressed circulating miRNAs in gestational diabetes mellitus and their effects in heart disease
miRNA Regulation in human
pregnancy
Ref. Heart disease Mechanism and outcome Ref.
miR-125b-
5p
↑ serum in first trimester,
normalizes in second and
third
[138] Mouse LAD ligation ↓ bak1, ↓ klf13 →
↓ cardiomyocyte apoptosis
[139]
miR-183-
5p
↑ serum, first trimester
↓ serum, third trimester
[138] Rat cardiac IRI ↓ VDAC1 → ↓ apoptosis [140]
miR-200b-
3p
↑ serum, first trimester
↓ serum, third trimester
[138] Mouse STZ-induced diabetic
cardiomyopathy
↓ CD36, ↓ EndoMT →
↓ cardiac fibrosis
↓ cardiac dysfunction
[141,
142]
miR-21-3p ↑ plasma [143,
144]
Mouse TAC and Ang II infusion ↓HDAC8 expression + Akt/Gsk3β signaling→
↓ cardiac hypertrophy
[145]
miR-195-
5p
↑ plasma [146] Mouse STZ-induced diabetic
cardiomyopathy
↓ miR-195-5p → ↑ Bcl-2, ↑ sirtuin 1 → ↓ cardiac
hypertrophy, ↓ ROS, ↓ apoptosis, ↑ myocardial
capillary density, ↑coronary blood flow
[147]
Rat cardiomyocytes ↓ miR-195-5p → ↑ SGK1 → rescues hERG
potassium ion channel deficiency
[148]
miR-29a ↓ serum [149] Zucker diabetic fatty rats ↓ miR-29a → ↓ mcl-1 [150]
Rat myocardial cells stimulated with
high glucose
↓ IGF-1 → ↑ apoptosis [151]
miR-222 ↓ serum [149] Mice with diabetic cardiomyopathy ↓ Wnt/ β-catenin signaling →
↓ EndoMT → ↓ cardiac fibrosis, ↑ cardiac
function
[152]
IRI in cardiomyocyte-specific miR-222
OE mice
↓ p27/HIPK1/Hmbox-1 →
↑ growth/proliferation,
↓ apoptosis
[152]
miR-222 OE in mice ↓ p27 → ↑ mTOR signaling, ↓ autophagy →
↑ hypertrophy, ↑ fibrosis, ↑ dysfunction with age
[153]
Akt/Gsk3β protein kinase B/glycogen synthase kinase 3 beta, Ang II angiotensin II, bak1 Bcl2 homologous antagonist/killer, Bcl-2 B cell lymphoma 2, CD36 cluster of
differentiation 36, EndoMT endothelial to mesenchymal transition, HDAC8 histone deacetylase 8, hERG human Ether-a-go-go-Related Gene, HIPK1 homeodomain
interacting protein kinase 1, Hmbox-1 homeobox containing 1, I/R ischemia/reperfusion, IGF-1 insulin-like growth factor 1, IRI ischemia/reperfusion injury, klf13
kruppel-like factor 13, LAD left anterior descending, Mcl-1 myeloid cell leukemia 1, MI myocardial infarction, miR microRNA, mTOR mammalian target of rapamycin,
OE overexpression, ROS reactive oxygen species, SGK1 serum/glucocorticoid regulated kinase 1, STZ streptozotocin, TAC transverse aortic constriction, VDAC1
voltage-dependent anion-selective channel 1, Wnt wingless-related integration site
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miR-222 in a cardiomyocyte-specific manner develop car-
diac hypertrophy, fibrosis, and dysfunction with age [153].
Here, miR-222 represses p27, leading to activation of
mTOR signaling and subsequent inhibition of autophagy.
Dysregulated miRNAs in preeclampsia and gestational
hypertension
Numerous studies have shown differential expression of
circulating miRNAs in pregnant females with PE, as has
been reviewed previously [158, 159]. Here, we will focus
on some of the prominent miRNAs that are known to
play a role in adverse cardiac remodeling and HF (Fig. 1
and Table 2).
Upregulated miRNAs in preeclampsia
Elevated circulating levels of both miR-210-3p and miR-
210-5p have been found in PE patients in several studies
[160–163]. MiR-210, a hypoxia-activated miRNA, is up-
regulated in the heart in pathological hypertrophy and
HF [192]. Interestingly, however, miR-210 seems to be
cardio-protective. In cardiomyocytes, Akt was shown to
increase miR-210 expression leading to reduced ROS
and cell death, most likely by targeting programmed cell
death protein 4 (PDCD4) mechanism [164, 165]. Add-
itionally, miR-210 inhibits cell-cycle inhibitor adenoma-
tous polyposis coli (APC), and miR-210-overexpressing
female mice exhibited reduced cardiomyocyte apoptosis,
upregulated angiogenesis, and overall improvement in
cardiac function after MI [166]. A similar effect was ob-
served in exosome-derived miR-210 that inhibits the
angiogenesis modulator ephrin A3 (Efna3), thus promot-
ing cardiac angiogenesis after MI in male mice [167].
In contrast to the downregulation in GDM, plasma
miR-29a is upregulated in mild PE compared to healthy
pregnant controls [168]. The miR-29 family plays dual
roles in cardiac remodeling and HF [155]. In patients
with hypertrophic cardiomyopathy, plasma miR-29a was
found to be upregulated and to positively correlate with
both cardiac hypertrophy and fibrosis [169, 170]. In
TAC-induced cardiac pressure overload in male mice, inhib-
ition of miR-29a attenuated cardiac hypertrophy and fibrosis
[170]. However, miR-29a has also been shown to protect
against phenylephrine-induced cardiomyocyte hypertrophy
by directly targeting the pro-hypertrophic NFATc4 [171].
Circulating levels of specific miRNAs in PE may be dif-
ferent based on disease severity. miR-21 and -155 have
been shown to be elevated in the plasma of PE patients,
upregulated approximately 5–8-fold in severe PE com-
pared to mild PE [160]. While its role remains controver-
sial, miR-21 is thought to be one of the most dysregulated
and abundantly expressed miRNAs in hypertrophic and
failing hearts [193]. Increased miR-21 expression has been
shown to induce cardiomyocyte hypertrophy by mediating
crosstalk between cardiac fibroblasts and cardiomyocytes.
MiR-21 inhibits sprout homolog 1 (Spry1) in cardiac fibro-
blasts, enhancing ERK MAPK signaling, leading to en-
hanced cardiac fibrosis and cardiomyocyte hypertrophy
upon TAC-induced cardiac pressure overload in male mice
[172]. MiR-21 also promotes cardiac fibrosis after MI in
male mice by directly targeting small mothers against deca-
pentaplegic 7 (SMAD7), a negative regulator of the TGF-
β1 signaling [173]. However, cardio-protective effects of
miR-21 are also reported. In a male rat model of cardiac
ischemia/reperfusion, miRNA-21 protected against cardio-
myocyte apoptosis by targeting PDCD4 [174]. In male
mice, miR-21 attenuated cardiac dysfunction and inflam-
matory signaling after MI by directly targeting kelch repeat
and BTB (POZ) domain containing 7 (KBTBD7), a modu-
lator of p38 MAPK and NFκB signaling [175]. MiR-155 is
a key mediator of cardiac inflammation and hypertrophy.
MiR-155-deficient mice exhibited dampened cardiac
hypertrophy upon TAC-induced pressure overload, most
likely by relieving miR-155-induced inhibition of histone
demethylase jumonji, AT rich interactive domain 2 (Jarid2)
[176]. Loss of miR-155 in macrophages was shown to pro-
mote cardiomyocyte hypertrophy in a paracrine manner in
male mice [177]. Here, miR-155 directly targets pro-
hypertrophic suppressor of cytokine signaling 1 (Socs1).
Additionally, miR-155 deficiency in male fibroblasts im-
proved cardiac function and remodeling after MI through
targeting tumor protein p-53-inducible nuclear protein 1
(TP53INP1) gene [178].
Interestingly, differences in circulating miRNA expres-
sion already before the onset of clinical symptoms may
be predictive of PE development. Plasma miR-206 was
upregulated in asymptomatic patients in the early third
trimester who later developed PE compared to those
who had a healthy pregnancy [179]. In male mice, miR-
206 was shown to exacerbate TAC-induced cardiac
hypertrophy by targeting tumor suppressor, Forkhead
box protein P1 (FoxP1) [180]. Whether circulating miR-
206 remains differentially expressed at the time of clin-
ical PE manifestation remains to be elucidated.
Downregulated miRNAs in preeclampsia
Multiple studies have found plasma and serum miR-144
levels to be downregulated in PE patients compared to
healthy controls, in various stages of disease progression
[160, 161, 168]. Loss of miR-144 in male mice was
shown to lead to impaired extracellular matrix remodeling
after MI, leading to cardiac dysfunction. Here, miR-144
targets zinc finger E-box binding homeobox 1 (Zeb-1), a
mediator of mesenchymal transition important for a
proper fibrotic response after injury [181]. Conversely, in-
jection of miR-144 mimics improved cardiac function
after MI in mice by reducing fibrosis, inflammation, and
apoptosis [182]. Additionally, loss of miR-144 in male
mice enhances injury after MI by targeting Ras-related C3
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Table 2 Differentially expressed circulating miRNAs in preeclampsia and their effects in heart disease
miRNA Regulation in
human pregnancy
Ref. Heart disease Mechanism and outcome Ref.
miR-210-3p and
miR-210-5p
↑ serum [160–163] Hypoxic cardiomyocytes,
mouse and rat
↑ Akt → ↑ miR-210 → ↓ PDCD4 →
↓ ROS, ↓ cell death
[164, 165]
Mouse LAD ligation ↑ miR-210-3p → ↓ APC → ↓ cardiomyocyte apoptosis,
↑ angiogenesis, ↑cardiac function
[166]
Mouse LAD ligation ↑ miR-210-3p in mesenchymal stem cells-derived
extracellular vesicles → ↓ Efna3 → promote cardiac
angiogenesis post-MI
[167]
miR-29a ↑ plasma [168] Patients with hypertrophic
cardiomyopathy
↑ miR-29a → ↑ cardiac hypertrophy, ↑fibrosis [169, 170]
Mouse TAC ↓ miR-29a → ↓ cardiac hypertrophy, ↓fibrosis [170]
ET-1 in H9c2 cardiomyocytes ↓ NFATc4 → ↓ cardiomyocyte hypertrophy [171]
miR-21 ↑ plasma [160] Mouse, cardiac fibroblast-
derived exosomes
↑ crosstalk between cardiac fibroblasts and
cardiomyocytes → ↑
cardiomyocyte hypertrophy
[172]
Mouse TAC ↓ Spry1, ↑ ERK-MAPK activity →
↑ fibroblast survival, ↑ growth factor secretion →
↓ fibrosis, ↓ cardiac hypertrophy
[172]
Mouse post-MI via LAD ligation ↓ SMAD7 → ↑ cardiac fibrosis post-MI [173]
Rat IRI ↓ PDCD4 → ↓ apoptosis post-MI [174]
Mouse LAD ligation ↓ miR-21 → targets KBTBD7 (p38 MAPK and NFκB
modulator) → ↓ cardiac dysfunction/inflammatory
signaling
[175]
miR-155 ↑ plasma [160] miR-155-KO mice TAC ↓ miR-155 → ↑ jumonji/Jarid2 →
↓ cardiac hypertrophy
[176]
miR-155 KO macrophages ↑ Socs1 → ↑ cardiomyocyte hypertrophy [177]
fibroblast miR-155-KO ↓ TP53INP1→ ↑ cardiac remodeling [178]
miR-206 ↑ plasma [179] Mouse with TAC-induced
cardiac hypertrophy
↑ miR-206 → ↓ tumor suppressor FoxP1→ ↑ TAC-induced
cardiac hypertrophy
[180]
miR-144 ↓ plasma and ↓ serum [160, 161, 168] miR-144-KO mouse LAD
ligation
↑ Zeb-1→ impaired fibrotic response post-injury →
cardiac dysfunction
[181]
Mouse LAD ligation ↑ miR-144 mimic injection →
↓ fibrosis, ↓inflammation, ↓apoptosis → ↑cardiac function
[182]
miR-144-KO mouse ↓ Rac-1 → ↑ ROS [183]
miR-125b-5p ↓ plasma [184] Mouse LAD ligation ↓ bak1, ↓ klf13 →
↓ cardiomyocyte apoptosis
[139]
miR-195-5p ↓ plasma [184, 185] Severe PE patients Unknown mechanism NA
↑ plasma [186] PE patients ↑ sFLT1 levels [186]
Mouse Ang II infusion ↑ miR-195-5p → ↓ FBXW7/MFN2 → ↑ mitochondrial
membrane depolarization/ROS production →
↑ cardiomyocyte hypertrophy
[187]
miR-126 ↓ serum [161] miR-126-KO mice LCA ligation ↑ Spred1 → defective angiogenesis [188]
Human cardiac microvascular
endothelial cells
↑ miR-126 → ↑ PI3K/Akt,
↑ VEGF, ↑SOD expression → hypoxia/reoxygenation
injury protection
[189]
miR-204 ↓ serum [161] Mouse LAD ligation ↑ miR-204 → ↓ LC3-II [190]
miR-15b ↓ serum [161] Mouse TAC overload ↑ miR-15b → ↓TGFβ signal(p38 MAPK/TGFβR-1 →
↑ cardiomyocyte hypertrophy, ↑ fibrosis
[191]
Akt protein kinase B, Ang II angiotensin II, APC adenomatous polyposis coli, ECM extracellular matrix, Efna3 angiogenesis modulator ephrin A3, ERK-MAPK
extracellular signal-regulated kinases/mitogen-activated protein kinase, ET-1 endothelin 1, FBXW7 F-box and WD repeat domain containing 7, FoxP1
Forkhead box protein P1, IRI ischemia/reperfusion injury, Jarid2 jumonji, AT rich interactive domain 2, KBTBD7 kelch repeat and BTB domain-containing
protein 7, KO knockout, LAD left anterior descending, LC3-II microtubule-associated protein 1 light chain 3, LC3-II microtubule-associated protein 1 light
chain 3, LCA left coronary artery, MFN2 mitofusion 2, MI myocardial infarction, miR microRNA, NFATc4 nuclear factor of activated T cells 4, NFκB nuclear
factor kappa-light-chain-enhancer of activated B cells, p38 MAPK mitogen activated protein kinase p38, PDCD4 programmed cell death protein 4, PE
preeclampsia, PI3K/Akt phosphatidylinositol 3-kinase/protein kinase B, RAC-1 Ras-related C3 botulinum toxin substrate 1, ROS reactive oxygen species, sFLT1
fms-like tyrosine kinase 1, SMAD7 small mothers against decapentaplegic 7, Socs1 cytokine signaling 1, SOD superoxide dismutase, Spry1 sprouty RTK
signaling antagonist 1, TAC transverse aortic constriction, TGFβR-1 transforming growth factor beta receptor I, TP53INP1 tumor protein p-53-inducible
nuclear protein 1, VEGF vascular endothelial growth factor, Zeb-1 zinc finger E-box binding homeobox 1
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botulinum toxin substrate 1 (Rac-1), a key component of
NADPH oxidase, which results in elevated ROS levels
[183].
In contrast to observed upregulation in GDM, plasma
miR-125b-5p and miR-195-5p are shown to be downregu-
lated in severe PE compared to healthy controls [184,
185]. However, elevated plasma miR-195-5p has also been
reported in PE patients, where it positively correlates with
sFLT1 levels [186]. In male mice, miR-195-5p promotes
Angiotensin II-induced cardiomyocyte hypertrophy by
targeting its downstream targets, tumor suppressor
FBXW7, and mitofusin 2 (MFN2), which are known to in-
hibit mitochondrial membrane depolarization and ROS
production [187].
Strikingly, differences in circulating miRNA expression
levels before clinical PE symptoms are apparent may be
predictive of future disease. Serum levels of miR-126, miR-
204, and miR-15b in early gestation were found to be
downregulated in women who developed severe PE in the
third trimester, compared to women who developed a
healthy pregnancy [161]. Endothelial cell and vascular in-
tegrity are regulated by miR-126. It was demonstrated that
miR-126 represses the anti-angiogenic modulator sprouty-
related, EVH1 domain-containing protein 1 (Spred1), lead-
ing to defective angiogenesis after MI in miR-126-deficient
mice [188]. Furthermore, miR-126 protects human cardiac
microvascular endothelial cells against hypoxia/reoxygena-
tion injury by activating PI3K/Akt signaling and increasing
VEGF and SOD expression [189]. MiR-204 seems to play a
role in autophagy modulation. It was demonstrated that
miR-204 may target cardiomyocyte microtubule-associated
protein 1 light chain 3 (LC3-II), which is important for
autophagosome formation, in cardiac ischemia/reperfusion
injury in rats [190]. Lastly, miR-15b was demonstrated to
inhibit several components of the TGFβ signaling pathway
in cardiomyocytes including p38 MAPK and TGFβ recep-
tor 1 (TGFβR-1), with in vivo miR-15b antagonism leading
to enhanced cardiomyocyte hypertrophy and fibrosis upon
TAC-induced pressure overload in mice [191].
Dysregulated miRNAs in gestational hypertension
GH and PE are related but distinct disorders, which is
reflected in the circulating miRNA profile of PE and GH
patients (Fig. 1 and Table 3). For instance, serum levels
of miR-29a were shown to be increased in both PE
patients and GH patients compared with normotensive
patients [194]. Furthermore, plasma miR-125b-5p was
downregulated in both PE and GH patients [184]. Inter-
estingly, however, serum miR-181a was shown to be ele-
vated in GH patients compared to normotensive and PE
patients, in whom no difference in serum miR-181a
levels was found [194]. It has been reported that miR-
181a plays several roles in HF. Elevated plasma miR-
181a has been suggested to be a marker of acute MI,
where miR-181a levels positively correlate with the oxida-
tive stress marker lipid hydroperoxide [195]. In a male rat
model of MI, cardiac miR-181a expression increases over
time and was shown to be associated with enhanced ex-
pression of the extracellular matrix components collagen I
and fibronectin by directly targeting the anti-fibrotic TGF-
β type III receptor in cardiac fibroblasts [196]. However,
in a rat model of pressure overload cardiac hypertrophy
via abdominal aortic constriction, cardiac miR-181a was
reported to be downregulated. Downregulation of miR-
181a in cardiomyocytes led to enhanced hypertrophy due
to enhanced autophagy and expression of miR-181a target
autophagy-mediated protein 5 (ATG5) [197].
Dysregulated miRNAs in peripartum cardiomyopathy
While not many differentially-expressed circulating miR-
NAs have been identified in PPCM, the miRNAs that
are known have directly been shown to contribute to
PPCM cardiac pathophysiology (Fig. 1 and Table 4).
Table 3 Differentially expressed circulating miRNAs in gestational hypertension and their effects in heart disease
miRNA Regulation in human pregnancy Ref. Heart disease Mechanism and outcome Ref.
miR-29a ↑ serum [194] Patients with hypertrophic
cardiomyopathy
↑ miR-29a → ↑ cardiac hypertrophy, ↑fibrosis [169, 170]
Mouse TAC ↓ miR-29a → ↓ cardiac hypertrophy, ↓fibrosis [170]
ET-1 in H9c2 cardiomyocytes ↓ NFATc4 → ↓ cardiomyocyte hypertrophy [171]
miR-125-5p ↓ plasma [184] Mouse LAD ligation ↓ bak1, ↓ klf13 →
↓ cardiomyocyte apoptosis
[139]
miR-181a ↑ serum [194] Human with AMI or
unstable angina
↑ oxidative stress marker lipid hydroperoxide [195]
Rat LAD ligation ↓ TGF-β type III receptor in cardiac fibroblasts
→ ↑ collagen I, ↑ fibronectin
[196]
Rat abdominal aortic
constriction
↓ miR-181a → ↑ ATG5 → ↑ hypertrophy [197]
AMI acute myocardial infarction, ATG5 autophagy-related 5, GH gestational hypertension, LAD left anterior descending, MI myocardial infarction, miR microRNA,
TGF-β transforming growth factor-beta
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In plasma, serum, and myocardium of PPCM patients,
miR-146a is well-known to be elevated [62, 198]. PPCM-
associated anti-angiogenic 16kDa-PRL induces miR-146a
expression via NFκB in endothelial cells [62]. It has been
shown that miR-146a inhibits proliferation and enhances
apoptosis of endothelial cells by repressing the proto-
oncogene neuroblastoma RAS viral oncogene homolog
(NRAS) [62]. Additionally, miR-146a is packed into
endothelial cell-derived exosomes which can be taken up
by cardiomyocytes [62]. In cardiomyocytes, miR-146a
dampens metabolic activity through inhibition of receptor
tyrosine-protein kinase erbB-4 (ERBB4), an important
modulator of physiological pregnancy-induced cardiac
hypertrophy [62]. Indeed, in both the STAT3-deficient
PPCM female mouse model and PPCM patients, miR-
146a is upregulated while ERBB4 expression is decreased
compared to healthy controls [62].
Besides miR-146a, in the LV of STAT3-deficient PPCM
male mice and PPCM patients miR-199a-5p was found to be
upregulated [61, 199]. Here, decreased STAT3 levels induced
miR-199a-5p-mediated ERBB4 inhibition in cardiomyocytes,
leading to reduced glucose uptake by the heart, ROS produc-
tion and cell death [199]. Furthermore, decreased STAT3
levels in cardiomyocytes were shown to induce miR-199a-
5p-mediated repression of the ubiquitin-proteasome system
(UPS) by repressing ubiquitin-conjugating enzymes Ube2g1
and Ube2i [61]. This ultimately leads to cardiomyocyte sarco-
mere disarray. Additionally, miR-199a-5p-mediated UPS
dysfunction leads to enhanced secretion of asymmetric
dimethylarginine (ADMA) from cardiomyocytes. In turn, se-
creted ADMA lowers nitric oxide bioavailability for cardiac
endothelial cells, leading to endothelial dysfunction and
apoptosis [61].
Future perspectives and concluding remarks
In this review, we summarize current knowledge on
pregnancy-related cardiovascular complications that may
lead to cardiac dysfunction during pregnancy in previously
healthy women, emphasizing the possible role of miRNAs
in the cardiac pathophysiology of these complications.
Since about 12% of pregnancy-related deaths in the
USA have been attributed to HF, and since GDM, PE,
GH, and PPCM have been associated with a short- and
long-term risk of HF development and death, there is a
necessity for novel diagnostic and prognostic markers
and therapeutic targets [9–12]. Circulating miRNAs have
been proposed to fulfill these needs in both cardiac dys-
function and pregnancy-related complications [159, 200].
While the mounting data on circulating miRNA expres-
sion in pregnancy complications is promising, some
discrepancies exist between studies. Such discrepancies
may be due to differences in isolation and profiling of miR-
NAs either from plasma or serum, population characteris-
tics, gestational age, internal controls, or normalization
methods [159, 200].
Connecting circulating miRNAs in pregnancy-related
cardiovascular complications to adverse cardiac remodel-
ing and dysfunction in pregnancy remains understudied
and further research needs to be conducted. However,
several hurdles must be overcome. Firstly, all but a few
studies have not directly linked circulating miRNAs to
cardiac pathology since human cardiac tissue samples
from pregnant women are scarce. Therefore, animal
models provide an attractive alternative to further study
the mechanisms and therapeutics of cardiovascular com-
plications and HF in pregnancy. Although rodent preg-
nancies differ vastly from human pregnancies and not all
aspects of human pregnancy can be translated in rodents,
both do have similar cardiovascular adaptations to preg-
nancy [201]. Secondly, the majority of mechanistic studies
into the roles of miRNAs in cardiac dysfunction have been
performed in male animals. A growing body of evidence
points towards differences in miRNA regulation of cardiac
remodeling and HF between males and females [202, 203],
Table 4 Differentially expressed miRNAs in peripartum cardiomyopathy
miRNA Regulation in human pregnancy Ref. Heart disease Mechanism and outcome Ref.
miR-146a ↑ plasma [62, 198] Cardiomyocyte-restricted
STAT3-KO mice
↑miR-146a → ↓NRAS →
↓ EC proliferation, ↑ apoptosis
[62]
↑ miR-146a in cardiomyocytes →
↓ ERBB4 → ↓ metabolic activity
[62]
miR-199a ↑ LV tissue [61, 199] Cardiomyocyte-restricted
STAT3-KO mice
↑miR-199a-5p → ↓ERBB4 in
cardiomyocytes → ↓glucose uptake,
↑ROS, ↑cell death
[199]
↑miR-199a-5p → ↓ Ube2g1/Ube2i →
cardiomyocyte sarcomere disarray
↑miR-199a-5p → ↑ ADMA secretion
from cardiomyocytes → ↓ NO
bioavailability, ↑ cardiac EC dysfunction,
↑ apoptosis
[61]
ADMA asymmetric dimethylarginie, EC endothelial cell, ERBB4 Erb-B2 receptor tyrosine kinase 4, KO knockout, LV left ventricle, miR microRNA, NO nitric oxide, NRAS
NRAS proto-oncogene, ROS reactive oxygen species, STAT3 signal transducer and activator of transcription 3, Ube2g1 ubiquitin-conjugating enzyme E2 G1, Ube2i
ubiquitin-conjugating enzyme E2 I, UPS ubiquitin-proteasome system
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thus posing an extra translational hurdle into the role of
miRNA in cardiac remodeling and HF in pregnant fe-
males. Thirdly, miRNAs have been shown to exert oppos-
ite effects on cardiomyocytes and cardiac fibroblasts,
leading to varied disease outcomes [155, 193]. Therefore,
it is important to delineate from which cell-types the al-
tered circulating miRNAs in pregnancy complications ori-
ginate and on which cardiac cell types their modulatory
effects are the largest. Lastly, differences in circulating
miRNA expression already before the onset of clinical
symptoms have been reported in PE [161, 179]. Focusing
on such early-response miRNAs will aid in developing
true prognostic biomarkers for pregnancy-related heart
disease.
Perspectives and significance
While existing data from different heart disease models are
promising, further investigation is needed to directly and
causally link miRNAs to cardiac pathophysiology in cardio-
vascular complications of pregnancy, which will aid in im-
proved diagnosis and development of novel therapies.
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